Point Biopharma Global Inc (PNT) Return on Investment ROI from the third quarter of 2023 to third quarter of 2022 and for the year 2023, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Point Biopharma Global Inc   (NASDAQ: PNT)


Point Biopharma Global Inc's ROI from its third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Point Biopharma Global Inc's ROI in the third quarter of 2023?
Point Biopharma Global Inc achieved a return on average invested assets (ROI) of 20.6 % in its third quarter of 2023, this is above PNT's average return on investment of -140.36%.
Point Biopharma Global Inc invested over the 12 months ending in its third quarter of 2023 $469 million

ROI fell compared to the second quarter of 2023, despite the net income growth of % from the second quarter of 2023.

Within the Healthcare sector 46 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2023 from 220 to 321.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Investment Change TTM 83.97 % 78.22 % 43.33 % 30.94 % 19.32 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 439 457 481 499 309
Return On Investment (TTM) 20.6 % 22.31 % 26.11 % 31.14 % -31.07 %
PNT's Overall Ranking # 321 # 220 # 235 # 192 # 0
Seq. Investment Change TTM 7.45 % 16.04 % 19.12 % 23.87 % 4.09 %
Seq. Net Income Change TTM -0.78 % -0.85 % -0.15 % - -
Net Income (TTM) in Millions 97 97 98 98 -79

PNT Company Profile >> Back to PNT Roi Comparisons >> See Annual PNT Return On Investment



Return On Investment PNT's Ranking
Within: No.
Industry # 20
Sector # 47
Overall # 321

Return On Investment Statistics
High Average Low
31.14 %
-140.36 %
-1373.2 %
(Dec 31 2022)   (Jun 30 2020)







Financial Statements
Point Biopharma Global Inc's III. Quarter Investments $ 439 Millions PNT's Balance sheet
Point Biopharma Global Inc's III. Quarter Income $ -25 Millions Quarterly PNT's Income Statement
PNT's Income by Division See PNT's Income by Division


PNT Annual Return On Investment (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020

Total Investments in Millions 499 255 137 0 0
Y / Y Investment Growth 95.31 % 86.62 % - - -
Net Income in Millions 98 -46 0 0 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment 19.71 % -17.98 % -0.23 % - -


Annual Roi Comment
In the fiscal year 2022 ROI improved to 19.71 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PNT's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PNT's Competitors
Subscribers only: Roi for Point Biopharma Global Inc's Suppliers
Subscribers only: Return On Investment for PNT's Customers

Other Ratios
PNT's Roa PNT's Inventory Turnover Ratio PNT's Growth Rates PNT's Dividend Statistics
PNT's Profitability Ratios PNT's Asset Turnover Ratio PNT's Dividend Growth
PNT's Roe PNT's Valuation Ratios PNT's Financial Strength Ratios PNT's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2023, within Healthcare Sector ROI
Cv Sciences Inc   51.59 %
Elite Pharmaceuticals Inc   47.02 %
Gyre Therapeutics Inc   45.47 %
Star Equity Holdings Inc   44.42 %
Idexx Laboratories Inc  43.85 %
Entera Bio Ltd   41.70 %
Zymeworks Inc   39.50 %
Medpace Holdings Inc   38.76 %
Lite Strategy Inc   38.41 %
Enzo Biochem Inc  38.07 %
Northview Acquisition Corp  37.67 %
Mettler toledo International Inc   33.97 %
Semler Scientific inc   30.96 %
Escalon Medical Corp   30.94 %
Nrc Health  30.72 %
Vaso Corporation  29.37 %
Denali Therapeutics Inc   29.23 %
Shockwave Medical Inc   28.94 %
Arcturus Therapeutics Holdings Inc   28.09 %
Johnson and Johnson  25.57 %
Protalix Biotherapeutics inc   25.29 %
Tao Synergies Inc   24.90 %
Harmony Biosciences Holdings inc   23.56 %
Voyager Therapeutics Inc   23.09 %
Iradimed Corporation  21.83 %
Vertex Pharmaceuticals Inc  20.88 %
Pro dex Inc   20.79 %
Point Biopharma Global Inc   20.60 %
Tenax Therapeutics Inc   19.63 %
Bellicum Pharmaceuticals Inc   19.61 %

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.